Regeneron-Licensed Obesity Drug Olatorepatide Delivers Up to 19% Weight Loss in Positive Phase 3 China Trial
Summary
Regeneron announced positive topline Phase 3 results for olatorepatide, a dual GLP-1/GIP receptor agonist licensed by the company, from a trial conducted in Chinese patients. The drug demonstrated significant efficacy, with participants achieving up to 19% mean body weight loss at week 48, and exhibited a favorable gastrointestinal tolerability profile compared to other dual incretin trials. This positive clinical update follows a recent positive opinion from the European Medicines Agency for another Regeneron product, and provides a strong counterpoint to general concerns about pipeline regulatory delays mentioned in the company's recent 10-K. These robust results position olatorepatide as a potentially competitive entrant in the high-value obesity market, with Regeneron holding exclusive development and commercial rights outside of Greater China. The company plans to initiate its global Phase 3 registrational program later this year, and investors will be closely watching its progress and further data presentations.
At the time of this announcement, REGN was trading at $741.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.3B. The 52-week trading range was $476.49 to $821.11. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.